Paraoxonase and arylesterase activities in fibromyalgia

Redox Report

Volumn 12, Issue 3, 2007, Pages 134-138

  Altindag, Ozlem ^a   Gur, Ali ^b   Calgan, Nazife ^b   Soran, Neslihan ^a   Celik, Hakim ^a   Selek, Sahabettin ^a  

^a HARRAN UNIVERSITY   (Turkey)

^b DICLE UNIVERSITY   (Turkey)

Author keywords

Arylesterase; Fibromyalgia; Oxidative stress; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; LIPID; THIOL DERIVATIVE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FIBROMYALGIA; HUMAN; LABORATORY TEST; LIPID ANALYSIS; MALE; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPECTROPHOTOMETRY;

EID: 34547117603     PISSN: 13510002     EISSN: None     Source Type: Journal    
DOI: 10.1179/rer.2007.12.3.134     Document Type: Article

References (31)

1. Ozgocmen S. New strategies in evaluation of therapeutic efficacy in fibromyalgia syndrome. Curr Pharm Des 2006; 12: 67-71
2. Altindag O, Celik H. Total antioxidant capacity and the severity of the pain in patients with fibromyalgia. Redox Report 2006; 11: 131-135.
3. Bagis S, Tamer L, Sahin G et al. Free radicals and antioxidants in primary fibromyalgia: An oxidative stress disorder? Rheumatol Int 2005; 25: 188-190.
4. Ozgocmen S, Ozyurt H, Sogut S, Akyol O, Ardicoglu O, Yildizhan H. Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns. Rheumatol Int 2006; 26: 598-603.
5. Rowat SC. Paraoxonase/MCS. Environ Health Perspect 1999; 107: 395.
6. Pall ML. Common etiology of posttraumatic stress disorder, fibromyalgia, chronic fatigue syndrome and multiple chemical sensitivity via elevated nitric oxide/peroxynitrite. Med Hypotheses 2001; 57: 139-145.
7. Hotopf M, Mackness MI, Nikolaou V et al. Paraoxonase in Persian Gulf War veterans. J Occup Environ Med 2003; 45: 668-675
8. Aslan M, Kosecik M, Horoz M, Selek S, Celik H, Erel O. Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anemia. Atherosclerosis 2007; 191: 397-402.
9. Serdar Z, Aslan K, Dirican M, Sarandol E, Yesilbursa D, Serdar A. Lipid and protein oxidation and antioxidant status in patients with angiographically proven coronary artery disease. Clin Biochem 2006; 39: 794-803.
10. Stadtman ER, Levine RL. Protein oxidation. Ann NY Acad Sci 2000; 899: 191-208.
11. Stocker R, Keaney Jr JF. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381-1478.
12. Schwenke DC. Antioxidants, dietary fat saturation, lipoprotein oxidation and atherogenesis. Nutrition 1998; 12: 377-379.
13. La Du BN. Is paraoxonase-3 another hdl-associated protein protective against atherosclerosis? Arterioscler Thromb Vasc Biol 2001; 21: 467-468.
14. Aviram M, Rosenblat M. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol 2005; 16: 393-399.
15. Katz RS, Wolfe F, Michaud K. Fibromyalgia diagnosis: A comparison of clinical, survey, and American College of Rheumatology criteria. Arthritis Rheum 2006; 54: 169-176.
16. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-1138.
17. Haagen L, Brock A. A new automated method for phenotyping arylesterase (EC 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992; 30: 391-395.
18. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004; 37: 112-119.
19. Nourooz-Zadeh J. Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods Enzymol 1999; 300: 58-62.
20. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82: 70-77.
21. Hu ML, Louie S, Cross CE, Motchnik P, Halliwell B. Antioxidant protection against hyochlorous acid in human plasma. J Lab Clin Med 1993; 121: 257-262.
22. Witztum JL, Steinberg D. The oxidative modification hypothesis of atherosclerosis: Does it hold for humans? Trends Cardiovasc Med 2001; 11: 93-102.
23. Haidara MA, Yassin HZ, Rateb M, Ammar H, Zorkani MA. Role of oxidative stress in development of cardiovascular complications in diabetes mellitus. Curr Vasc Pharmacol 2006; 4: 215-227.
24. Van Guilder GP, Hoetzer GL, Greiner JJ, Stauffer BL, Desouza CA. Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obes Res 2006; 14: 2127-2131.
25. Arlt S, Kontush A, Muller-Thomsen T, Beisiegel U. [Lipid peroxidation as a common pathomechanism in coronary heart disease and Alzheimer disease]. Z Gerontol Geriatr 2001; 34: 461-465.
26. Ali M. The cause of fibromyalgia: The respiratory-to-fermentative shift (the DysOx State) in ATP production. J Integrat Med 2003; 8: 135-140.
27. Gur M, Aslan M, Yildiz A et al. Paraoxonase and arylesterase activities in coronary artery disease. Eur J Clin Invest 2006; 36: 779-787.
28. Aslan M, Nazligul Y, Horoz M et al. Serum paraoxonase-1 activity in Helicobacter pylori infected subjects. Atherosclerosis 2007; In press.
29. Verit FF, Celik H, Yazgan P, Erel O, Geyikli I. Paraoxonase-1 activity as a marker of atherosclerosis is not associated with low bone mineral density in healthy postmenopausal women. Arch Gynecol Obstet 2007; 275: 353-359.
30. Sumegova K, Blazicek P, Waczulikova I, Zitnanova I, Durackova Z. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks. Acta Biochim Pol 2006; 53: 783-787.
31. Altindag O, Erel O, Aksoy N, Selek S, Celik H, Karaoglanoglu M. Increased oxidative stress and its relation with collagen metabolism in knee osteoarthritis. Rheumatol Int 2007; 27: 339-344.